Stock Quote Notification for Eli Lilly and Company

Eli Lilly and sent this email to their subscribers on November 30, 2024.

Company: Eli Lilly and Company
Ticker: LLY
Exchange: NYSE
Last Trade: $795.35
Change: 7.16
% Change: +0.91%
Volume: 2,206,918
Day's High: $800.33
Day's Low: $789.33
Previous Close: $788.19

Text-only version of this email

Eli Lilly and Company Company: Eli Lilly and Company Ticker: LLY Exchange: NYSE Last Trade: $795.35 Change: 7.16 % Change: +0.91% Volume: 2,206,918 Day's High: $800.33 Day's Low: $789.33 Previous Close: $788.19

Show all

The Latest Emails Sent By Eli Lilly and

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

More Emails, Deals & Coupons From Eli Lilly and

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity